ReviewResearch (Washington, D.C.)2025
Innovative Atherosclerosis Models: Advancing Pathophysiology and Translational Research.
Review in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- A bioinspired long-acting chlorhexidine-eluting super-hydrophilic coating on vascular catheters prevents thrombosis and biofouling.Bioactive materials · 2027Article
- Single-cell sequencing-guided discovery of narciclasine as a dual VCAM-1/ICAM-1 inhibitor for atherosclerosis management.Genes & diseases · 2027Article
- An albumin-armed fibronectin fragment assembly on stents enables immune evasion, thrombosis prevention, and self-adaptive vascular cell selectivity.Bioactive materials · 2026Article
- Recent Advances in 3D-Printed Bioresorbable Vascular Stents: Toward Patient-Specific, Novel-Structured, Functional, and Smart Devices.ACS omega · 2026Review
- The PVAT-MAMs Axis in Atherosclerosis: A Hypothesis-Driven Cross-Scale Conceptual Framework.International journal of molecular sciences · 2026Review
- Surface Charge-Determined Protein Coronas of Nanoparticles Control Endothelial Cells Uptake Under Low Magnitude Shear Stress.Exploration (Beijing, China) · 2026Article
- Nanotechnology for atherosclerotic plaque stabilisation: bridging innovation and clinical practice.EBioMedicine · 2026Review
- RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside.Research (Washington, D.C.) · 2026Article
- Bioinspired Ruthenium Arene Complex with Pseudo-Vacant Coordination Sites as Efficient Small-Molecular Antioxidant Enzyme Mimics for Preventing Vascular Restenosis.Research (Washington, D.C.) · 2026Article
- Biomimetic Mammary Gland Organoid-on-a-Chip for Producing Selected Human Milk Components.Research (Washington, D.C.) · 2026Article
- Isoginkgetin, a natural biflavonoid from Ginkgo biloba, inhibits inflammatory response in endothelial cells via suppressing NF-κB activation.Acta pharmacologica Sinica · 2025Article
- Metabolic reprogramming in ischemic stroke: when glycolytic overdrive meets lipid storm.Cell death & disease · 2025Review
- Mechanistic insights into the multi-target anti-atherosclerotic actions of rhubarb: a traditional remedy revisited.Chinese medicine · 2025Review
- Revisiting the role of GDF15 in atherosclerosis in mouse and human.Acta pharmacologica Sinica · 2025Article
- Microfluidic Perfusable Pathological Vasculature for Atherosclerosis Drug Screening.Research (Washington, D.C.) · 2025Article
- Evolutionary Patterns of Collagen Fiber Arrangement and Calcification in Atherosclerosis.Research (Washington, D.C.) · 2025Article
- Smart Thrombosis Care: The Rise of Closed-Loop Diagnosis-to-Treatment Nano Systems.International journal of nanomedicine · 2025Review
- PCSK9 Promotes Atherosclerotic Plaque Instability by Inducing VSMC Ferroptosis through the YAP1-NUPR1 Axis.Research (Washington, D.C.) · 2025Article
- Long-Term Brain-Computer Interface Functional Electrical Stimulation Enhances Neuroplasticity and Functional Recovery in Elderly Stroke: A 4.5-Year Longitudinal Study Integrating Electroencephalography Biomarkers and Clinical Assessments.Research (Washington, D.C.) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS) is a chronic inflammatory condition influenced by glucose and lipid disorders, oxidative stress, and thrombosis, reflecting the complexity of its pathological process. The development of accurate experimental models that simulate human AS is essential for understanding its initiation and progression. This review summarizes the current AS research models and analyzes their specific application scenarios. We discuss tissue-engineered blood vessels (TEBVs) and vessels-on-a-chip (VoCs), which leverage tissue engineering and precise microenvironmental control to construct in vitro models that closely resemble the structure and function of human AS. Isolated vessel segments from live animals provide a valuable tool for investigating human AS due to their physiological similarity, controllability, and reproducibility. The review further outlines the construction of AS animal models through high-fat diets and gene-editing techniques, highlighting how immune-inflammatory responses, mechanical arterial injury, and hemodynamic changes accelerate model development. This comprehensive analysis highlights the potential of AS models to revolutionize theranostic applications in clinical translational research, paving the way for more personalized and effective treatments for AS in the near future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.